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Immunotherapy of HIV: On the Horizon?
Why should the correctional HIV provider care
about T cells, T cell epitopes, and HLA mole-
cules? Because the use of Strategic Treatment
Interruption (STI) and therapeutic vaccines for
the treatment of HIV – particularly acute HIV
infection – may be on the horizon for our
patients. This article will describe the compo-
nents of immune response to HIV and explain
why STI is more likely to provide benefit in acute
HIV infection and less likely to benefit patients
who have chronic HIV infection, at least until
more effective forms of STI, such as STI given in
conjunction with effective therapeutic HIV vac-
cines, are developed. It should be noted that STI
is not an FDA approved use of any of the HAART
drugs, and that STI should never be attempted
outside of well-established experimental proto-
cols run by experts in the field.
HIV immunology 101
The cellular immune response is the first arm of
the immune system to respond to HIV infection
(see HEPPigram). Cellular immune response is
provided by T helper cells (also known as CD4+
cells or T4 cells) and cytotoxic T cells (also
known as CTL, or CD8+ or T8 cells). Studies of
acutely infected HIV patients have shown that
each individual mounts a cellular immune
response to HIV that determines the individual’s
“set point”, the point of stabilization of viral load
after acute infection has been controlled. This
set point is closely linked to progression to
AIDS.1 Patients whose immune systems do not
successfully control HIV during acute infection
have higher set points and more rapid progres-
sion to AIDS than patients whose immune sys-
tems do not perform as well during acute infec-
tion.
The ability to control HIV and obtain a lower set
point is determined by several factors (illustrated
in Figure 1). These factors include the initial
dose of HIV during infection, the type of virus
transmitted, i.e. the specific viral DNA and pro-
tein sequences, the HLA of the infected individ-
ual, and the number of T cell epitopes that can
be recognized by the individual’s T cells.
Dose of HIV
Numerous studies have clearly demonstrated
that the initial dose of infecting virus can deter-
mine outcome. For example, patients who
received blood donations containing large
amounts of HIV (such as hemophiliacs, prior to
screening of factor VIII) appear to progress more
rapidly than patients who are infected via sex or
through minor intravenous exposures.2 Mother
to child transmission is also dependent on viral
load (particularly at the time of delivery).
Individuals who are infected with smaller doses
may have a lower viral burden at the outset, and
perhaps more importantly, may be infected with
fewer quasispecies or viral variants. Just as it is
easier to control HIV with HAART when starting
from a lower total viral load, it may be easier to
obtain immune control of HIV when there are
fewer viral variants.
HLA and inheritance
The HLA molecule carries pieces of HIV viral
proteins in its central “binding groove” to the sur-
face of infected cells. When T cells see a piece
of an HIV protein (a short piece called a peptide)
on the surface of the cell, carried by the HLA pro-
tein, they react, either by killing the infected cell
(the function of CTLs) or by secreting messages
that amplify the immune response to HIV (T
helper cells). HIV peptides that bind to HLA and
turn on T cells are called epitopes. These epi-
topes tell the immune system that HIV is pre-
sent, and it needs to begin to fight. So HIV epi-
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Figure1. Factors determining “set point” and
viral load in the setting of acute HIV infection
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topes are the “key” that turns on the immune
defense against HIV.
There are many different types of HLA mol-
ecules (different alleles of the following HLA
genes: HLA A, B, C, DR, DQ, DP). Different
HLA molecules present different epitopes;
the epitopes they are able to present are
determined by the pattern of the amino acids
in the HIV peptide. (If the HLA is a lock, only
certain epitopes with a particular pattern fit
the lock). Since HLA are genetically encod-
ed, some individuals may be able to use epi-
topes (that have the right pattern for their
HLA) that others cannot (because the
sequences don’t match the pattern for their
HLA).
New information on the
role of HLA
One of the key findings in HIV over the past
two years has been that the genetic back-
ground (HLA) of an HIV-infected individual
can determine how well they are able to
control their HIV. The role of HLA has been
reported previously3,4 but the mechanism of
interaction between the HLA and the out-
come of infection was less clear until recent
data was published in the New England
Journal. Mary Carrington, one of the lead
authors, demonstrated the link between
selected HLA molecules (a variant of B35)
and HIV virus sequence.5 She showed that
the HLA variant in question did not effective-
ly present a T cell epitope. (To use our
metaphor, the key did not fit the lock). Other
HLA were able to present the epitope. This
epitope appeared to play a critical role in the
immune response to HIV for these patients.
Thus, a person’s genetic background (HLA)
determines how many epitopes their
immune system is able to recognize. The
ability to recognize some specific epitopes
appears to be linked to control of infection.
One of the HLA types that appears to be
associated with more rapid progression so
far is a variant of HLAB35.6 HLA Types that
are associated with better oucomes include
HLA B27 (a rare haplotype) and HLA B577.
It may not be long before we begin HLA typ-
ing our HIV patients so as to predict the
course of their infection.
T cells and Epitopes
T cell response to HIV epitopes has been
shown to be a critical determinant of out-
come: patients who have more T cell
responses to many different pieces of HIV
(epitopes) appear to be more likely to con-
tain HIV infection.8,9 Broad T cell response to
many HIV epitopes appears a major deter-
minant of the HIV setpoint.8 Broad T cell
response is also seen in long-term non-pro-
gressors.10 Most of the epitopes that have
been mapped are cytotoxic T cell (CTL) epi-
topes. T helper cells (Th) also play an impor-
tant role in early immune response to HIV,
but since they are destroyed in chronic HIV
infection, researchers are only beginning to
understand their role in HIV. They appear to
play an important role in early infection. Th
cells that respond to HIV are destroyed or
inactivated in the setting of chronic infection
since it is these Th or CD4+ T cells that are
the target of the virus. Rebuilding the supply
of Th and CTL that respond to HIV epitopes
is one of the goals of STI and therapeutic
vaccination.
Virus sequence and 
quasispecies
Different HIVs have different DNA
sequences, due to the error-prone RT
enzyme whose function is to enable the
virus to replicate in the host cell. The RT
makes mistakes, and as a result, variants of
the original HIV are created. Some of these
variants are not viable, however, others are.
In acute infection, the variability of the strain
is minimal. In chronic infection, the variabili-
ty of HIV infecting the individual host
expands. The swarm of variants that devel-
op in the course of HIV infection are called
quasispecies. The number of quasispecies
expands as infection progresses.11
The development of quasispecies appears
to have an adverse impact on the ability of
the immune system to contain the virus. In
early infection, response to a few epitopes
may effectively contain the virus. In late HIV
infection, response to many different epi-
topes may still fail to contain infection,
because of the number of variant viruses.
Furthermore, if the patient has HLA that can-
not present epitopes contained in the virus
sequence, there will be only the minimum
CTL response. Alternatively, as the HIV
evolves into quasispecies, some isolates
evolve in which the original epitopes recog-
nized by the host immune system have been
altered and no longer bind to the host HLA
(these are called escape mutants).
The theory behind STI:
Boost and Broaden 
T cell responses
The goal of STI is to “broaden immune
response”. From the above discussions, it is
clear that the type of immune response that
needs to be broadened is the T cell
response. This can be achieved by vaccina-
tion, however, there only a few HIV vac-
cines under study in clinical trials (see HIV
101). In the absence of effective vaccines,
proponents of STI have argued that allowing
the patient to develop a response to his or
her own virus, by “autologous vaccination” is
a reasonable approach. Opponents of STI
note that autologous vaccination involves
allowing live, virulent autologous virus that
has already been poorly controlled in the
absence of drug treatment to replicate and
potentially seed more sites in the body.
In general, patients who are undergoing STI
are given HAART until viral replication has
been completely suppressed below
detectable levels (< 50 copies per ml), for
long durations of time (eight months in some
cases). Then the HAART is stopped, and the
patient’s virus is allowed to rebound up to a
certain level (up to 50,000 copies on one
occasion or above 5,000 copies on two
occasions, for example). This cycle of
HAART treatment followed by treatment
interruption is continued until there is sus-
tained suppression of the viral load.
Following several cycles of STI, in most
cases, the viral rebound is smaller.
One potential benefit of STI that has been
observed is that rebound virus tends to be
“wild type”, a strain lacking any viral muta-
tions that had been developed in the course
of HAART. However, when HAART is
resumed in the course of STI, some
researchers have observed that mutant drug
resistant strains re-emerge (since they have
only been archived in resting T cells). The
same may be true for CTL escape mutants,
however, data is lacking.
According to STI theory, subjects who are
undergoing HAART treatment are able to
recover immune function during the period
of viral suppression. Stopping HAART
allows autologous virus to rebound, and
expands the number of T cells that respond
to the virus. If the viral load reaches a dan-
gerous level, HAART is restarted and the
viral load returns to baseline (below 50
copies in most cases). Opponents of STI
have pointed out that HAART may allow
CD4 T cell counts to increase but few, if any,
of these T cells are programmed to fight
HIV.12 Suppression of viral rebound may be
due to broader CTL response, but it may
also be due to assistance by T helper cells,
particularly in early HIV infection.13
The role of CD8+ T cells (CTL) in containing
HIV infection was recently confirmed in an
animal model.14 In this model, acutely infect-
ed rhesus macaques who were treated with
tenofovir (the new Gilead drug) and demon-
strated subsequent suppression of a highly
virulent strain of the SIV (simian HIV) also
showed substantial resistance to subse-
quent intravenous rechallenge with homolo-
gous and highly heterologous SIV isolates,
up to more than one year later, despite the
absence of effective (neutralizing) antibody
directed against the virus. However, when
CD8 T cells were depleted by the
researchers, the amount of viremia rose by
as much as 100,000 fold. Viremia returned
to low levels as soon as CD8+ cells were
restored. This study showed a positive effect
of STI in early infection and confirmed the
critical role of CD8 T cells (CTL) in control-
ling infection after STI.
STI and acute infection
The most successful studies of STI have
focused on the treatment of acutely infected
HIV subjects. Bruce Walker and colleagues
(Boston, MA) have reported on 14 subjects
who underwent repeated cycles of STI.15 Of
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Dear Colleagues,
Many of our correctional patients experience recurring cycles of excellent viral suppression
followed by interruption of therapy (in parallel with their cycles of release and reincarceration).
These cycles of therapy are a form of “unsupervised and unstructured treatment interruption”
(USTI). Since USTI is a recurring theme of correctional HIV care, we chose to describe recent
studies of Strategic Treatment Interuption (STI) and the interactions between T cells, HLA, and
HIV for our main article this month. This article also gives our Chief Editor an opportunity to wear
her immunology hat. When not providing care to incarcerated women in the Connecticut prison
system, she is involved in the development of HIV vaccines for prevention and treatment of HIV
at Brown University.
Our main article in this issue describes the components of immune response to HIV and explains
why STI is more likely to provide benefit in acute HIV infection and less likely to benefit patients
who have chronic HIV infection, at least until more effective forms of STI, such as STI given in
conjunction with effective therapeutic HIV vaccines, are developed. Our HIV 101 lists vaccines
that are currently under investigation for use with STI. The HEPPigram describes the course of
immune response to HIV infection over time, and in response to HAART.
In this issue, the Ask The Expert piece is on HIV-1 non-clade B infections. The case discusses
the specific issues of recognizing, testing for, and treating HIV-1 non-clade B infections. This
month’s expert is our own Chief Editor, Dr. Anne De Groot.
Since correctional HIV patients frequently experience what may be called USTI, correctional HIV
providers have an opportunity to contribute some information on the effect of USTI on our
patients. How would we expect USTI to compare to STI? Poorly. For example, many of our
patients do not achieve suppression of viral replication of long enough duration prior to interrupt-
ing therapy (typically, in STI, treatment is continued for at least 8 months before STI is attempt-
ed). Secondly, the duration of HAART cessation may occur over periods of months (sometimes
years), much longer than the duration of treatment interruption evaluated in STI studies.
Furthermore, our patients frequently resume therapy, when they are reincarcerated, with viral
loads vastly exceeding the limits used in STI studies. In addition, our patients usually resume
illicit drug use when they interrupt their HAART. Resumption of injection drug use and the
associated life circumstances may adversely impact the immune response to “autologous immu-
nization.” In short, USTI has none of the features that may contribute to the success of STI in
acute HIV infection. Experts in the field caution against the application of STI until more informa-
tion can be obtained on the optimal duration of the individual cycles, the role of HLA, the role of
T cell epitopes, and the role of adjunctive treatments such as vaccines.
As always, we encourage your feedback and submissions for future issues of HEPP News!
Sincerely,
David P. Paar, M.D.
Letter from the Editor
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4the first 14 subjects, seven were able to
achieve persistent control of viremia. Four
achieved control after a single treatment ces-
sation, two after a second STI, and one after
a third STI. Several other studies have been
reported where treatment was ceased entire-
ly (Treatment cessation, not equivalent to
STI), after initial optimal or suboptimal treat-
ment of acute infection. Many of the subjects
in these two studies appeared to be able to
control viremia (4 out of 10 in one study16, 2
out of 7 in another study17). Whether the
number of patients who controlled infection
following treatment cessation is any different
than the number that would be able to con-
trol infection without therapy is unknown at
this point.
STI and chronic infection
In general, studies of the use of STI in chron-
ically infected patients have not shown any
benefit. One reason may be that HAART
does not as effectively suppress HIV replica-
tion in chronic HIV. In a large study of 128
subjects18, only 54 subjects were able to
completely suppress HIV replication during
the cycles of HAART therapy, only 9 of these
had viral loads lower than 5,000 copies after
completion of the STI cycles. Chronically
infected patients also have greater viral
diversity, so boosting immune responses to
the virus by “autologous immunization” may
not have the same effect as this treatment in
the setting of acute infection, where viral
variability is less and response to the same
number of CTL epitopes may be able to con-
tain infection.
Vaccines as Immunotherapy
HIV-1 vaccines in development fall roughly
into three categories: recombinant proteins,
vectored vaccines, and "replicons" (highly
engineered viral vectors).
The vaccine that has been used most often
in the setting of immunotherapy is Remune,
a vaccine developed by the Salk Institute
and now licensed to a subsidiary of Agouron
(Immune Response Corp). Remune is an
inactivated, protein-depleted, HIV virus.
Several cycles of inactivation are carried out
so as to assure the safety of the vaccine.
Studies of Remune in the treatment of chron-
ic infection have been recently published.
Although CD4 T cell counts were significant-
ly higher, no impact on viral load, or clinical
course could be demonstrated.19 The vac-
cine may have a role when used in conjunc-
tion with STI (see below). Thus far, studies of
therapeutic vaccination of chronically infect-
ed patients with any of the vaccines
approved for human use have failed to
demonstrate substantial benefits.
Vaccination as an adjunct
to STI
Investigators from the Aaron Diamond AIDS
Research Center have explored the potential
for therapeutic vaccination in 14 subjects
started on HAART within 90 days of HIV
infection. This study was reported at the 8th
CROI in Chicago, 2001, and reviewed in
HEPP (February 2001). Subjects received 4
doses of a vaccine cocktail that included the
canary pox vector vCP1452, expressing HIV
gag, pol, env, and nef genes, as well as a
recombinant HIV protein, gp160. This was
the first study to incorporate a vaccine proto-
col into STI; while the results weren’t alto-
gether exciting, the procedure appeared to
be safe.20
A second study was carried out combining
STI and Remune vaccination. This study was
reported at the AIDS Vaccine 2001 meeting
in September of this year.21 The slope of the
initial rise in plasma vRNA was significantly
slower (0.16 vs. 0.21 log10 copies/day) in
the Remune vs. control group (p < 0.05). The
frequency of cells that produce IFN-gamma
when stimulated with several HIV proteins
was significantly increased in the Remune
group. Therapeutic immunization with
Remune appeared to increase both CD4 and
CD8 T-cell immunity to HIV antigens and
altered the kinetics of viral
rebound during the treatment. Viral load and
T cells returned to baseline after cessation of
HAART, so the long term benefits of this
approach are not yet clear.22
STI and USTI
Correctional HIV patients frequently experi-
ence what may be called unstructured treat-
ment interruptions (USTI) because of numer-
ous barriers to effective care that may exist
in prisons today. Our patients more often
experience interruptions because they expe-
rience side effects or have comorbidities
such as liver disease that are exacerbated
by HAART. Furthermore, these patients may
be mentally ill and stop taking prescriptions
or choose to drinking or taking drugs again
and this interferes with their adherehence.
Bad care while incacerated does occur but is
just one of many reasons that patients have
USTI. How does USTI compare to STI?
Poorly. For example, many of our patients do
not achieve suppression of viral replication of
long enough duration. Secondly, the duration
of HAART cessation may occur over periods
of months (sometimes years), much longer
than the duration of treatment interruption
evaluated in STI studies. Furthermore, our
patients frequently resume therapy, when
they are reincarcerated, with viral loads vast-
ly exceeding the limits used in STI studies. In
addition, our patients usually resume drug
use when they interrupt their HAART.
Resumption of injection drug use and the
associated life circumstances may adversely
impact the immune response to “autologous
immunization”. In short, USTI has none of
the features that may contribute to the suc-
cess of STI in acute HIV infection. Experts in
the field caution against the application of
STI until more information can be obtained
on the optimal duration of the individual
cycles, the role of HLA, the role of T cell epi-
topes, and the role of adjunctive treatments
such as vaccines.
In conclusion, STI is a treatment that is on
the horizon, particularly for modulation of
acute HIV infection. Much remains to be
learned about the optimal use of this strate-
gy. Investigations related to these new treat-
ments have expanded our understanding of
immune response to HIV, and therefore may
help us understand why some patients do
well, and others worse, in the setting of a
standardized approach to HIV treatment.
Providers practicing in correctional settings
probably have much greater experience with
unstructured treatment interruption (USTI)
than providers practicing in with non-incar-
cerated populations do. We may be in an
excellent position to perform observational
studies and teach our non-correctional peers
about the outcomes of USTI. The next poten-
tial venue for this type of report would be the
9th CROI to be held in Seattle, Washington.
(http://www.retroconference.org.) On the
topic of treatment interruptions we have
much to learn from our academic colleagues,
and perhaps, even more to contribute.
GLOSSARY
T cell- Lymphocyte possessing either helper
properties, assisting other cells in the body to
respond to infection (a.k.a. T helper cells) or
lytic properties (a.k.a. killer T cells, or
Cytotoxic T cells /CTL).
MHC- Short for the Major Histocompatability
Complex. This is the molecule present on the
outside of cells that presents peptides to the
immune system. It acts as the carrier for
pieces of the HIV virus (or any other virus or
bacteria in the cell). Each person has six
MHC genes (and may be heterozygous at all
six loci). These molecules determine trans-
plant rejection (hence the MHC name) and
response to infections.
HLA- Short for Human Leukocyte Antigen.
These proteins are genetically determine
molecules that sit on the surface of antigen
presenting cells. They play a key role in the
presentation of immune stimuli to T cells.
Essentially, HLA is the name that refers to
the human MHC.
T cell epitope- Only a small piece of a virus,
a peptide known as an epitope, will bind in
the binding groove of each MHC. Mutations
of the peptide can make binding, and hence
immune response, impossible to detect
(escape mutations). Alternatively, the patient
can possess a variant of HLA to which criti-
cal HIV epitopes cannot bind. (see NEJM).
Immunotherapy of HIV...
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Viral quasi species- The HIV viri-
on’s error-prone RT makes mis-
takes, and as a result, variants of the
original infecting isolate of HIV are
created. The swarm of variants that
develop in the course of HIV infec-
tion are called quasi species. The
number of quasispecies expands as
infection progresses.
Escape mutation- HIV isolates that
have evolved in which the original
epitopes recognized by the host
immune system have been altered
or replaced and the new peptides
no longer bind to the host HLA or are
not recognized by the T cells.
Treatment cessation- Arresting
HAART after initiation. (Without fur-
ther cycles of intermittent therapy).
Structured Treatment Interruption
(STI)- Cycles of HAART followed by
cycles of no treatment. Viral load is
closely monitored and treatment is
resumed when viral load rises to a
detrimental level.
Unstructured Treatment
Interruption (USTI)- Not an investi-
gational regimen, however one that
is observed for many incarcerated
individuals, due to failure to resume
therapy (for any number of rea-
sons) after release from prison or
jail. Cycles of HAART of inconsis-
tent duration followed by cycles of
interruption of variable duration.
Viral loads often achieve very high
levels before treatment is resumed.
HEPPigram: Natural Course of HIV Infection
Plus Antiretroviral Therapy
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Immunotherapy of
HIV... (continued from page 4)
Modified from Bartlett JG, Gallant JE. 2001-2001 Medical Management of HIV Infection. Online at
http://aids-hopkins.edu
Flipped Ratio: The CD4:CD8 ratio is usually approximately 2:1 but in HIV-infected people,
the ratio flips and is approximately 1:2.
HAART: Highly Active Antiretroviral Therapy
Set Point: The point around which viral load levels off without anti-HIV treatment. This
point is different for different individuals, i.e. rapid progressors generally have higher set
points. The idea of treatment is to lower the set point, lowering the viral load in the
patient’s body.
//
//
//
Ask the Expert: A New Infection with an Undetectable Viral Load
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Answer: Either the patient is an exception to the rule and a lucky
member of the “long term non-progressor” club, or the patient has
ongoing viral load replication not identified by viral load PCR of viral
replication. The latter is unfortunately more likely since you have
already seen a decline in the CD4 T cell count in a relatively short
period of time. Thus, you must consider the possibility that the viral
load assay is not detecting the virus, as it would in a case of non-
clade B infection.
What is non-clade B infection? As discussed in the main article in
this issue, HIV is a very variable virus. Just as the virus may evolve
during the course of an invidual infection to become a “swarm” of
different but related viruses, it has evolved into different but related
subtypes in different regions of the world over the course of the HIV
epidemic.
HIV-1 is broken down into 3 large groups, each believed to have
arisen from a distinct transmission event, from 3 different chim-
panzee viruses. The M group is the main group, which has dis-
persed throughout the world. The other two groups, O (outlier)
group and a rarely noted non-O, non-M group are only found in
West Africa and Cameroon. The M group of HIV-1 has been further
broken down into various subtypes, or clades, designated A through
K based on variability in the env and gag regions of the viral
genome. The predominant subtype in the United States and
Western Europe is HIV-1 subtype (clade) B. A is dominant in
Eastern Africa, C is dominant in Southern Africa, and a slightly dif-
ferent set of clade C viruses are dominant in India. In Southeast
Asia, B and E are the most prevalent. Intersubtype recombinations,
or “chimeras,” also known as circulating recombinant forms (CRFs)
are spreading in China and other areas of the world where the epi-
demic is just taking off. In the US and Europe, the epidemiology of
non-clade B infections is in flux, and recent reports suggest that
non-clade B subtypes are becoming more prevalent.1,2
On closer questioning, you find out that your patient’s sexual part-
ner formerly lived in New York City, where non-clade B viruses have
been detected. Since some viral load assays can be insensitive to
the presence of circulating virus, you repeat the viral load using a
branched chain DNA assay and you are now able to detect a posi-
tive viral load (75,000 copies per ml).
Although HIV antibody tests do detect non-clade B viruses, not all
viral load assays can detect virus in the presence of non-B subtypes
(eg, Roche Amplicor Version 1.0 or reverse transcriptase-poly-
merase chain reaction [RT-PCR] 1.0). Those that can detect it
(branched DNA [b-DNA], Nuclisens, Ultradirect Monitor) may do so
but there is a lot of variability between the tests.3 Now that you have
found a test that is able to detect the patient’s virus, you need to
stick with that assay to follow the course of infection. You can also
send her virus to be identified at the state Department of Health lab-
oratories.
Since she has acute HIV infection, she should probably be treated
with the goals of suppressing the initial burst of viral replication and
decreasing the magnitude of virus dissemination throughout the
body. This will potentially alter the initial viral set point which may
ultimately affect the rate of disease progression, possibly reducing
the rate of viral mutation, and preserving immune function.4 You
consult an expert in your community about whether it would be
appropriate to initiate treatment and with which medication. Your
colleague tells you that there may be some variability in the
response to treatment by clade or subtype, but that type of informa-
tion is simply not available because large numbers of individuals
with non-clade B subtypes have yet to be studied in detail. Thus
there is no reason to modify her regimen by subtype. Early infor-
mation from treatment of non-clade B infections in Africa suggest
that treatment responses are similar to those seen with clade B
strains.
The duration of treatment for acute HIV infection is currently not
known, however, if her VL becomes undetectable after about 6
months, it may be acceptable to stop treatment. You would of
course consult with your colleague, since you are not able to enroll
her in a study of STI (see main article).
Question: A 40 year-old woman is referred to you by the prison HIV counselor because she had a recent positive HIV test. She was tested
by one of the astute internists at your institution because she developed Bell’s Palsy about two months into her incarceration (a condition
not uncommonly associated with early HIV infection). She is surprised and dismayed by the diagnosis, since she never used injection drugs
and was monogamous during the period prior to her incarceration. She had, in fact, been tested for HIV when she applied for her immigra-
tion waiver, and she was HIV seronegative. That test was performed about two months prior to incarceration, about six months ago.
You do your best to reassure her, by explaining how a viral load test and CD4 T cell count will assist you both with a decision on the course
of treatment. You decide to repeat the HIV ELISA and Western Blot, just to be sure that the diagnosis is correct. You then arrange to have
her HIV studies drawn, and schedule a follow up appointment.
When her blood work returns, it is your turn to be surprised. She has an undetectable viral load. You recheck her HIV test, and it is indeed
positive (all the Western blot bands light up). Her CD4 T cell count is squarely in the normal range, however, on closer inspection you notice
that her CD8 to CD4 ratio has “flipped” (CD8 cells > CD4 cells). You worry that the viral load assay was mislabelled, so you repeat it, along
with another CD4 T cell count. Again, the viral load is undetectable but the CD4 is now slightly lower, at the low end of the normal range.
You repeat the test again, and the CD4 returns even lower. She is now five months into her incarceration, and you have evidence of fairly
rapid CD4 decline and no detectable viral load. What is going on and what should you do?
Anne S. De Groot, M.D., Brown Medical School, Editor, HEPP News
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7*proposed AIDS vaccine efficacy trials (See Newsflashes)
phase I trial: first stage trial, focusing on safety and toxicity, very small cohort
phase II trial: second stage trial, measures efficacy of vaccine in small cohort
phase II trial: last stage of experimental testing, pivotal trial measures efficacy on a larger scale
gp120: recombinant HIV envelope protein
ALVAC-HIV: a recombinant canarypox virus expressing multiple HIV genes
MVA-HIV: modified vaccinia Ankara (an attenuated vaccinia vector) expressing multiple HIV genes
NYVAC-HIV: an attenuated vaccinia vector expressing multiple HIV genes
TBC-3B: an attenuated vaccinia vector expressing multiple HIV genes
H
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1 HIV Vaccine Candidates by HEPP News Staff
VACCINE NAME
gp120
ALVAC-HIV
ALVAC-HIV
Lipopeptides LP5, LP6
Vaccinia TBC-3B
DNA-HIV
DNA-HIV, MVA-HIV
NYVAC-HIV
DNA-HIV, Adenovirus
HIV
VaxGen Canarypox
with HIV gag, protease,
and env +gp120
Canarypox with HIV
env, gag, protease, pol,
and nef, +gp120
HIV SUBTYPE
TARGETED
B/B, B/E
B, E
A
B
B
B
A
B
B
B/E
B/?
PRODUCING
COMPANY
Vaxgen
Aventis Pasteur
Aventis Pasteur
ANRS:
National Agency for AIDS
Research, France
Therion
Apolion
University of Oxford
Aventis Pasteur
Merck
U.S. Military, Royal Thai
Govt., Mahidol U., Aventis
Pasteur, VaxGen
NIH HVTN, Aventis
Pasteur, VaxGen
STATUS
Ongoing phase III trials in the United States
and Thailand
Ongoing phase II trials in the US, Haiti,
Brazil, Trinidad (subtype B); Thailand (sub-
type E); used alone or in combination with
gp120
Ready for Phase I trials in Uganda
Ongoing phase I trials in France
Ongoing phase I trials in the US
Completed phase I trials
Ongoing phase I trials in the UK and Kenya
Ready for phase I in the US
Ongoing phase I trials in the US
Earliest phase III start date: Summer 2002,
Thailand*
Earliest phase III start date: December
2002, U.S., Brazil, Haiti, Peru, Trinidad
(Possible: Argentina, Dominican Republic,
Honduras)*
Adapted from Johnston MI, Flores J. Progress in HIV Vaccine Development. Current Opinion in Pharmacology. 2001:1(5):504-520.
On the web at www.niaid.nih.gov/daids/vaccine/pdf/pc1506.pdf`. Additional Information from Science Magazine 2001 293 (5537):
1973.
As drug-resistant HIV virus becomes more and more common, physicians will need alternative methods of treating the virus. One of
the most promising of these methods is the development of a prophylactic or therapeutic vaccine. The following table provides infor-
mation on vaccines currently in the development pipeline.
Resources & Websites
AIDS Vaccine Websites:
NIH AIDS Vaccines Page
http://www.niaid.nih.gov/daids/vaccine
AIDS Clinical Trial Information Service
http://www.actis.org/
The Economics of AIDS Vaccines
http://www.iaen.org/vaccine/
The Body: AIDS Vaccines
http://www.thebody.com/treat/vaccines.html
AIDS Vaccine 2001 Conference
http://63.84.172.40/
The Global Alliance to Immunize against AIDS
http://www.gaiavaccine.org
AIDS Treatment Websites:
Updated Adult and Adolescent HIV Treatment guidelines
http://www.hivatis.org/guidelines/adult/Aug13_01/pdf/AAAug13S.PDF
AIDS Action: Publications on HIV and Corrections
http://www.aidsaction.org
Hopkins AIDS Service: Medical Management of HIV Infection
http://hopkins-aids.edu/publications/book/book_toc.html
Hepatitis Packets Available:
NATAP: 15-page handbook on HCV and HIV/HCV co-infection. Also
availabke in Spanish. Contact JuLev@aol.com
Hepatitis C Awareness Project: 14-page packet on HCV targeted
for and availble inmates and others. Contact pkbeckinor@aol.com
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National Conference on
Correctional Health Care
November 10-14, 2001
Albuquerque, New Mexico
Fee: $275 member,
$325 non-member
Call: 773.880.1460
Fax: 773.880.2424
Visit: www.ncchc.org
Bridging the Gap: HEPP
Preconference Symposium
November 10, 2001
1:30pm-5:00pm
Fee: Free with NCCHC
Conference Registration
3rd Annual National Corrections
Telemedicine Conference
November 18-20, 2001
Tucson, Arizona
Pre-registration (before Oct.19):
$450 government/non-profit;
$650 corporate
Registration (Oct. 20-Nov.18):
$500 government/non-profit;
$700 corporate
Call: 520.626.5243
Email: hatheway@u.arizona.edu
Visit: www.NCTC2001.com
CME and ANCC credit available
3rd International Hepatitis C
Update for the New Millennium
November 30-December 1, 2001
Houston, Texas
Fee: Physicians- $165; Other
Health Care Professionals- $135
Visit: www.uth.tmc.edu/cme
Email: Kristen.K.Brockman@
uth.tmc.edu
Call: 713.500.5127
CME and CEU credits available
41st Interscience Conference on
Antimicrobial Agents and
Chemotherapy
December 16-19, 2001
Chicago, Illinois
Preregistration extended
until November 19
Visit: www.icaac.org
9th Conference on Retroviruses
and Opportunistic Infections
February 24-28, 2002
Seattle, Washington
Call for Abstracts: Deadline:
October 23, 2001
Registration: Dec. 10, 2001-
Jan. 23, 2002
Call: 703.535.6899
Visit: www.retroconference.org
Save the 
Dates
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HEPATITIS
Giving Interferon Early: An Improved HCV
Treatment?
Washington Post, 10/02/01
According to the CDC, approximately 6,500 peo-
ple in the United States are infected with
Hepatitis C every year and 8,000-10,000 die
annually. A new study that will be published in
the New England Journal of Medicine in
November states that treatment with interferon
alfa-2b soon after infection may be an effective
anti-HCV therapy. In the study, 42 of 453 newly
infected patients received the full six months of
interferon treatment and became virus-free and
remained so after therapy termination. After 24
weeks of treatment, virus was undetectable in 42
out of 43 patients. Side effects include muscle
and joint aches, fever, headache, and some-
times depression or a reduction in white blood
cell count. The six-month treatment costs $6000.
New Treatment Regimen for Hepatitis C
Lancet 2001; 358:958-65
A new study has shown that treating HCV with
peginterferon alfa-2b plus ribavirin is more effec-
tive than treating with interferon alfa-2b plus rib-
avirin. The study measured the sustained viro-
logical response rate (SVR) and among geno-
type 1 HCV-infected individuals found a SVR of
42% for patients on the new treatment regimen
compared to a SVR of 33% among patients on
the old drug regimen. The new treatment regi-
men consists of 1.5mg/kg peginterferon (PEG-
Intron, Schering Corp) subcutaneously once a
week and 800mg oral ribivirin (Rebetol, Schering
Corp) daily for 48 weeks. Oral ribivirin (Rebetol)
is also available seperately.
HIV
Genetic Variation and HIV Progression
NEJM 2001;344:1668-1675
In a study of 850 HIV-positive people,
researchers found a genetic variation that may
be linked to the difference in progression time
from initial HIV infection to full-blown AIDS. The
gene is associated with the HLA locus (see main
article) and is called Px, and a certain variation in
this gene appeared to accelerate the onset of
full-blown AIDS to 4-5 years. The 12% of patients
in this study who had the genetic variation expe-
rienced full blown AIDS about 7 years post-infec-
tion compared to those without the variation who
progressed to AIDS 11-12 years post-infection.
Possible New Vaccine Trials
Science, 14 September 2001; 293: 1973
Both the NIH and the U.S. military have plans to
begin phase III efficacy trials of virtually identical
HIV vaccines. The vaccines consist of two parts:
the first is the "prime" dose that consists of HIV
genes in a canarypox vector and to trigger the
immune system to produce CTLs directed
against HIV infected cells. The second part of the
vaccine is genetically engineered gp120 used to
trigger the immune system to produce antibodies
that protect cells from becoming infected in the
beginning. Phase II trials, however, have shown
that approximately 30% of people develop the
CTL response the vaccine aims to produce. This
has caused controversy as to whether the phase
III trials should proceed. Some scientists doubt
the scientific basis of this trial while others have
taken the stance that 30% efficacy is better than
none.
Mortality Due to HIV Drops
CDC Release, 10/10/01
According to a CDC release entitled "Deaths:
Preliminary Data for 2000," the percentage of
deaths due to HIV declined 3.7% in 2000. This is
the fifth year in a row that deaths due to HIV
have declined, although HIV remains the leading
cause of death for all races in the 25 to 44 year-
old age group. The full report is available online
at the CDC’s National Center for Health Statistics
website at http://www.cdc.gov/nchs/
releases/01news/mort2k.htm.
Abused Women at Higher Risk for HIV
Infection
Family Planning Perspectives,
September/October 2001
According to a new report from the
Alan Guttmacher Institute’s Family Plan-
ning Perspectives, women who experienced var-
ious "household dysfunctions," including abuse,
as children are more likely to engage in risky
sexual behaviors putting them at higher risk for
contracting HIV. The study looked at how any
one of seven "household dysfunctions" women
experienced in childhood correlated with having
more than 30 sexual partners, having had sexu-
al intercourse before the age of 16, and perceiv-
ing oneself as at risk for HIV infection. Findings
correlated the household dysfunctions with
increased risk for infection with HIV, indicating a
long-term effect of childhood experiences on
sexual behavior.
Terrorist Attacks Affect Prisons
Tharp, New York Post, 10/4/01
In response to the terrorist attacks of September
11, 2001 stock prices of private prison compa-
nies sky rocketed in expectation of an increasing
number of detainees. Coincidentally, the Federal
Bureau of Prisons let out requests for bids for
two prisons to hold criminal aliens in Georgia.
This contract is the largest award this year from
the BOP with a requests for three more bids
early next year for prisons in the Southwest
deserts for over 1500 detainees. Additionally, pri-
vate prisons are looking to benefit from an
expected Supreme Court ruling that would make
it illegal for prisoners to sue private prisons for
civil rights violations. In the wake of the attacks,
private prisons are benefitting.
News Flashes
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Self-Assessment Test for Continuing Medical Education Credit
Brown Medical School designates this educational activity for 1 hour in category 1 credit toward the AMA Physician’s Recognition Award.
To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions.
A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through April 30, 2002.
The estimated time for completion of this activity is one hour and there is no fee for participation.
1. STI is an FDA approved use of HAART.
a) True
b) False
2. Which of the following tests do NOT have the ability to detect
non-clade B HIV-1 infections?
a) RT-PCR 1.0
b) branched-DNA (b-DNA)
c) Nuclisens
d) Amplicor Version 1.0
e) a and d
3. Which of the following factors determines the set point for HIV
infection?
a) Viral Dose
b) HLA
c) T cell Epitopes
d) Viral Sequence
e) all of the above
4. HIV viral quasispecies:
a) develop due to mistakes made by the RT enzyme
b) allow the immune response to effectively contain the virus
c) develop due to mistakes of the protease enzyme
d) lead to greater transmission of the virus from mother
to child
e) contribute to the destruction of CD8+ T cells
5. Which of the following HLA types are associated with a better
outcome in HIV infection (i.e. slower progression to AIDS)?
a) HLA B57
b) HLA B35
c) HLA B27
d) a and c
e) a and b
6. Interruption of effective HAART therapy, in the context of STI:
a) allows autologous virus to expand without being controlled
by HAART
b) allows virus to potentially seed new sites in the body
c) forces T cells that have been unable to contain autologous
infection to confront the virus again in the absence of any
assistance from HAART
d) allows the patient to develop T cell responses to
autologous virus
e) all of the above
BROWN MEDICAL SCHOOL • OFFICE OF CONTINUING MEDICAL EDUCATION • BOX G-A2 • PROVIDENCE, RI 02912
The Brown Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical
education activities for physicians.
The use of the Brown Medical School name implies review of the educational format and material only. The opinions, recommendations
and editorial positions expressed by those whose input is included in this bulletin are their own. They do not represent or speak for the
Brown Medical School.
For Continuing Medical Education credit please complete the following and mail or fax to 401.863.2660 or
register online at www.hivcorrections.org. Be sure to print clearly so that we have the correct information for you.
Name __________________________________________________________________ Degree ____________________
Address ____________________________________________________________________________________________
____________________________________________________________________________________________________
City ____________________________________________________ State ________ Zip ________________________
Telephone ________________________________________________ Fax ______________________________________
HEPP News Evaluation
5 Excellent 4 Very Good 3 Fair 2 Poor 1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
Main Article 5 4 3 2 1 5 4 3 2 1
HEPPigram 5 4 3 2 1 5 4 3 2 1
HIV 101 5 4 3 2 1 5 4 3 2 1
Save the
Dates 5 4 3 2 1 5 4 3 2 1
2. Do you feel that HEPP News helps you in your work?
Why or why not?
3. What future topics should HEPP News address?
4. How can HEPP News be made more useful to you?
5. Do you have specific comments on this issue?
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CME is Now Available Online at www.hivcorrections.org:
HEPP readers are now able to take HEPP News' continuing medical education (CME) tests online at http://www.HIVcorrections.org.
Any internet browser will enable you to take the HEPP News CME tests every month. Your test results will be registered with the
Brown Medical School Office for Continuing Medical Education. When you pass the test, you can either download your CME certifi-
cate from the website or request Brown to send the certificate in the mail. Try it out this week!
